Previous Section | Index | Home Page |
14 May 2008 : Column 1657Wcontinued
Data provided by the Health Protection Agency (HPA) are provided by HPA region, comprising nine regional offices covering the whole of England which correspond to the Government offices of the regions (this equates to SHA in all regions apart from the South East, which includes South Central and South East Coast SHAs).
Information on the proportion of multi-drug resistant TB cases in England from 1998 to 2006 reported to have had previous tuberculosis treatment is provided in the following table. Due to the small numbers and the potential for deductive disclosure, this information has been provided for England as a whole in each year. Among those cases reported to have previously been treated, it is not possible to definitively attribute drug resistance to previously unsuccessful TB treatment as some of these cases may have subsequently acquired a new infection.
Proportion of cases of multi-drug resistant( 1) TB with a previous history of tuberculosis, England, 1998 to 2006( 2) | |||
Previous history of TB | |||
Number | Percentage | Total number of multi-drug resistant cases | |
(1) Resistant to isoniazid and rifampicin, with or without resistance to other drugs. (2) Of cases with known previous history of tuberculosis. |
Following the publication by the World Health Organisation of the definition for extensively drug-resistant (XDR) TB in 2006, the HPA reviewed all cases reported from 2003 to 2006. A single case of XDR TB was identified in a patient reported in England in 2003. A further XDR case has been reported from Scotland in 2008.
A subsequent retrospective review was carried out by the HPA of drug susceptibility testing results, where these were available, on all tuberculosis isolates
reported in the United Kingdom from 1993 to 2002. A further six isolates were identified as conforming to the definition of XDR TB from this period.
Treatment outcomes are currently reported 12 months after the start of treatment. Multi-drug resistant and extensively drug-resistant TB cases require treatment for considerably longer than 12 months and outcome of treatment is not, therefore, routinely available in these cases.
Bob Spink: To ask the Secretary of State for International Development what UK bilateral aid programmes are under way in (a) Gambia, (b) Cameroon, (c) Guinea and (d) the Democratic Republic of Congo; and what the likely (i) cost and (ii) duration is of each. [204971]
Gillian Merron: The following tables show all the UK bilateral aid programmes with a value of £500,000 or more currently under way in the Gambia, Cameroon, Guinea and the Democratic Republic of Congo.
(a) Gambia | ||||
Commitment | ||||
Sector | Programme | £ million | From | To |
(c) Guinea | ||||
Commitment | ||||
Sector | Programme | £ million | From | To |
Next Section | Index | Home Page |